The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort - Marek - 2018 - Annals of Clinical and Translational Neurology - Wiley Online Library

Kenneth Marek, Institute for Neurodegerative Disorders, 60 Temple St, Suite 8A, New Haven, CT 06510. Tel: 203 4014353; Fax 203 401 4301; E-mail: kmarek@indd.org Sohini Chowdhury The Michael J. Fox Foundation for Parkinson's Research, New York, New York Andrew Siderowf University of Pennsylvania, Philadelphia, Pennsylvania Shirley Lasch Institute for Neurodegenerative Disorders, New Haven, Connecticut Christopher S. Coffey University of Iowa, Iowa City, Iowa Chelsea Caspell-Garcia University of Iowa, Iowa City, Iowa Tanya Simuni Northwestern University, Chicago, Illinois Danna Jennings Eli Lilly and Company, New York, New York Caroline M. Tanner University of California, San Francisco, California John Q. Trojanowski University of Pennsylvania, Philadelphia, Pennsylvania Leslie M. Shaw University of Pennsylvania, Philadelphia, Pennsylvania John Seibyl Institute for Neurodegenerative Disorders, New Haven, Connecticut Norbert Schuff University of California, San Francisco, California Andre

Kenneth Marek, Institute for Neurodegerative Disorders, 60 Temple St, Suite 8A, New Haven, CT 06510. Tel: 203 4014353; Fax 203 401 4301; E-mail: kmarek@indd.org Sohini Chowdhury The Michael J. Fox Foundation for Parkinson's Research, New York, New York Andrew Siderowf University of Pennsylvania, Philadelphia, Pennsylvania Shirley Lasch Institute for Neurodegenerative Disorders, New Haven, Connecticut Christopher S. Coffey University of Iowa, Iowa City, Iowa Chelsea Caspell-Garcia University of Iowa, Iowa City, Iowa Tanya Simuni Northwestern University, Chicago, Illinois Danna Jennings Eli Lill